Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | PPM1B | O75688 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15200245 | 1.00 | MAPT (0.53) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL12332811 | 1.00 | MAPT (0.53) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL13767916 | 0.94 | MAPT (0.49) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL24352202 | 0.92 | ALDH1A1 (0.57) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL22990900 | 0.92 | ALDH1A1 (0.57) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2375356 | 0.91 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL4221 | 0.91 | — | — | |
| SCHEMBL8891623 | 0.91 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL237380 | 0.91 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL999804 | 0.89 | MAPT (0.45) | MAPTALDH1A1PPM1BPTPN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030609-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND ENERGY STORAGE DEVICE USING SAME | UBE INDUSTRIES, LTD. (JP) | 2014-01-30 | — | — | US | claimed |
| US-4157435-A | TITANIUM, ALUMINUM, SILOXANE COORDINATION CATALYST | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1979-06-05 | — | — | US | claimed |
| CN-115557913-A | Benzoazaheterocyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3782994-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3390395-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
| US-20180118753-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| WO-2018034918-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-4507290-A | CONTRACEPTIVE | WORLD HEALTH ORGANIZATION (CH) | 1985-03-26 | — | — | US | disclosed |
| US-4157435-A | TITANIUM, ALUMINUM, SILOXANE COORDINATION CATALYST | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1979-06-05 | — | — | US | disclosed |
| US-4085276-A | CATALYST COMPOSED OF AN ORGANOMETALLIC COMPOUND AND THE REACTION PRODUCT OF A MAGNESIUM COMPOUND AND A TITANIUM COMPOUND | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JA) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118753-A1 | IDO Inhibitors | IDO1, IDO2, INMT | MAPT 2933/4885ALDH1A1 1338/4885PPM1B 1761/4885 |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | MAPT 1898/4885ALDH1A1 2489/4885PPM1B 2973/4885 |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | MAPT 1898/4885ALDH1A1 2489/4885PPM1B 2973/4885 |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | MAPT 1898/4885ALDH1A1 2489/4885PPM1B 2973/4885 |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | MAPT 4452/4885ALDH1A1 2728/4885PPM1B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.